We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.73%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$362M
AUM Growth
-$26.1M
Cap. Flow
-$33.3M
Cap. Flow %
-9.19%
Top 10 Hldgs %
27.18%
Holding
180
New
35
Increased
46
Reduced
71
Closed
24

Top Buys

1
ABVX
Abivax
ABVX
+$4.86M
2
NRIX icon
Nurix Therapeutics
NRIX
+$3.76M
3
IVA
Inventiva
IVA
+$3.75M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.21M
5
DFTX
Definium Therapeutics
DFTX
+$3.15M

Top Sells

1
VRDN icon
Viridian Therapeutics
VRDN
+$7.08M
2
COGT icon
Cogent Biosciences
COGT
+$5.16M
3
RVMD icon
Revolution Medicines
RVMD
+$5.14M
4
CDTX
Cidara Therapeutics
CDTX
+$5.06M
5
ACLX
Arcellx
ACLX
+$4.89M

Sector Composition

1 Healthcare 66.93%
2 Technology 9.01%
3 Industrials 5.47%
4 Consumer Discretionary 2.89%
5 Financials 2.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMO icon
176
Thermo Fisher Scientific
TMO
$198B
– –
-2,269
Closed -$1.31M
UNF icon
177
Unifirst Corp
UNF
$5.27B
– –
-7,727
Closed -$1.49M
VST icon
178
Vistra
VST
$52.4B
– –
-5,673
Closed -$915K
SEPN
179
Septerna Inc
SEPN
$1.51B
– –
-78,682
Closed -$2.19M
SNDK
180
Sandisk
SNDK
$201B
– –
-4,378
Closed -$1.04M
4 5 6 7
8

Similar funds

RWM
Revisor Wealth Management Akron, Ohio $362M AUM 15.97% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MSL
MILLINGTON SECURITIES, LLC Red Bank, New Jersey $362M AUM
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
CAP
Cordoba Advisory Partners New York $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return

HighVista Strategies's Q1 2026 Portfolio in Review

As of Q1 2026, HighVista Strategies held 180 positions worth $362M, down 6.7% from $388M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $33.3M in Q1 2026, closing 24 positions and reducing 71 holdings. Its most notable exit was Cidara Therapeutics, an estimated $5.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Nurix Therapeutics worth $3.51M.

  • HighVista Strategies's largest Q1 2026 buy was Nurix Therapeutics: 226,546 shares worth $3.51M.
  • HighVista Strategies added most to Abivax in Q1 2026, an estimated $4.86M increase.
  • HighVista Strategies's biggest Q1 2026 reduction was Viridian Therapeutics, cutting an estimated $7.08M.
  • HighVista Strategies fully exited Cidara Therapeutics in Q1 2026, selling an estimated $5.06M.
  • HighVista Strategies's ten largest holdings make up 27% of its $362M portfolio in Q1 2026.
  • HighVista Strategies opened 35 new positions and closed 24 in Q1 2026.
  • HighVista Strategies's portfolio value fell 6.7% quarter-over-quarter to $362M.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.